Markets

Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months

Oct 23, 2026 · 10:18 AM ET· updated 51m ago

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 AnalysisMedian Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-upOral Presentation at the

Why It Matters

Iovance's cancer medicine showed strong results in testing. Watch if doctors and regulators think this means it really works.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IOVA13.82

-0.32 (-2.26%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.